Animal models are foundational to Parkinson’s disease research. From studying dopamine neuron loss to evaluating potential therapies, in vivo systems allow researchers to explore the biology of disease in a physiologically relevant context. While in vitro tools like iPSC-derived neurons and organoidsare valuable, they can’t replicate the full complexity of Parkinson’s, including motor symptoms, inflammation, or circuitry disruption.

So what are the main types of animal models of Parkinson’s disease, what are they best suited for, and what do researchers need to consider when aligning animal models with their experimental goals?

Why we still rely on animal models in Parkinson’s disease research

Even as in vitro systems evolve, animal models remain essential for studying Parkinson’s disease at the organism level. They provide a unique window into functional impairments, neurodegeneration, and molecular pathology that unfold across interconnected systems.

Researchers turn to animal models of Parkinson’s disease to:

• Observe motor impairments over time
• Study dopaminergic neuron loss in vivo
• Investigate protein aggregation and clearance
• Evaluate therapeutic safety and efficacy

However, each animal model highlights different aspects of the disease. Understanding what your model captures (and what it doesn’t) can help you design more focused experiments.

Neurotoxin-based animal models

Neurotoxin-based models use chemicals that selectively damage dopaminergic neurons, triggering Parkinsonian symptoms in animals. These models are widely used to study motor dysfunction, dopamine depletion, and neuroinflammation.

6-OHDA

6-hydroxydopamine (6-OHDA) is typically used in rats, delivered via stereotaxic injection into the medial forebrain bundle or striatum. It creates targeted, unilateral lesions that result in reproducible motor impairments¹. This model is especially useful for behavioral assays and screening neuroprotective compounds.

MPTP

MPTP is a systemic neurotoxin, often used in mice. It crosses the blood–brain barrier and is metabolized into MPP⁺, which selectively targets dopaminergic neurons in the substantia nigra². The resulting dopamine depletion leads to motor deficits and inflammation. MPTP is widely used for modelling acute dopaminergic loss.

Genetic animal models

Genetic models replicate familial mutations associated with Parkinson’s disease. Most are developed in mice, although variants exist in rats, zebrafish, and Drosophila. These models allow researchers to explore disease mechanisms like protein aggregation, mitochondrial dysfunction, and vesicle trafficking under defined genetic conditions.

α-Synuclein

Mice that overexpress mutant α-synuclein (eg, A53T or A30P) develop progressive protein aggregation and synaptic dysfunction, mimicking features of Lewy body pathology³. These models are frequently used to study disease initiation and to test aggregation-targeted therapies.

LRRK2 and Parkin

Transgenic models expressing Parkinson's-linked mutations in LRRK2 (eg, G2019S) or Parkin reveal changes in mitochondrial function, lysosomal biology, and inflammation⁴. While phenotypes are often subtle, these models are essential for studying gene-environment interactions and longer-term pathology.

Integrated animal models: combining genetics, toxins, and immune context

Some models combine genetic susceptibility with environmental or immune triggers to reflect the multifactorial nature of Parkinson’s.

Dual-hit models

These mouse models combine α-synuclein overexpression with a neurotoxin (eg, MPTP or 6-OHDA), allowing researchers to study how protein aggregation and dopaminergic neuron loss interact⁵. Dual-hit systems are increasingly used to explore complex pathology, though they may be harder to standardize.

Humanized immune system models

These models engraft human immune cells into immunodeficient mice to study how peripheral immune responses affect neurodegeneration⁶. While technically demanding and still evolving, they offer a promising platform for investigating neuroimmune interactions in Parkinson’s disease.

Quick-look comparison of the animal models of Parkinson’s disease

Given the range of available models, it can be helpful to compare their core features side by side. The table below summarizes commonly used animal models in Parkinson’s disease research, highlighting their key characteristics:

Each model has its strengths and trade-offs. The key is to let your biological question lead you to the one that’s right for your research.

Choose a model that fits your research goals

Neurotoxin-based models like 6-OHDA or MPTP offer rapid, reproducible dopamine loss and are ideal for behavioral studies or early-stage drug testing. Genetic or integrated models provide deeper mechanistic insight for pathway-specific questions like aggregation, lysosomal dysfunction, or inflammation.

No model captures Parkinson’s in full. But choosing a system that reflects your biology of interest gives you more clarity, reproducibility, and meaningful results. Your research goals are specific. The model you choose should be too.

References

1. Blandini, F. & Armentero, M.-T. Animal models of Parkinson’s disease.  FEBS J.  279, 1156–1166 (2012).

2. Jackson-Lewis, V. & Przedborski, S. Protocol for the MPTP mouse model of Parkinson’s disease.  Nat. Protoc.  2, 141–151 (2007).

3. Giasson, B. I.  et al.  Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-synuclein.  Neuron  34, 521–533 (2002).

4. Cookson, M. R. LRRK2 pathways leading to neurodegeneration.  Curr. Neurol. Neurosci. Rep.  15, 42 (2015).

5. Song, L.-K.  et al.  Targeted overexpression of α-synuclein by rAAV2/1 vectors induces progressive nigrostriatal degeneration and increases vulnerability to MPTP in mouse.  PLoS ONE  10, e0131281 (2015).

6. Manocha, G. D.  et al.  Defining the contribution of neuroinflammation to Parkinson’s disease in humanized immune system mice.  Mol. Neurodegener.  12, 17 (2017).